Aldeyra Therapeutics, Inc. (ALDX) Thursday said that the U.S. Food and Drug Administration (FDA) has accepted the resubmitted New Drug Application (NDA) for reproxalap for the treatment of dry eye disease.
Prescription Drug User Fee Act (PDUFA) target action date, the date on which a decision from the regulator is expected, is December 16, 2025.
"Based on the FDA's requirement for an additional clinical trial demonstrating the efficacy of reproxalap in treating the symptoms of dry eye disease, and per agreement with the FDA, the NDA resubmission contained a single clinical trial that achieved the primary endpoint of reducing ocular discomfort relative to the vehicle control," stated Todd C. Brady, President and Chief Executive Officer of Aldeyra.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.